News

Annual High-Dose Vit. D Ups Fall, Fracture Risks


 

Far from protecting older women from falls and fractures, once-yearly high-dose oral vitamin D raised the risk of falls by 15% and that of fractures by 26%, according to a study by researchers in Australia.

As this study used the “largest total annual dose of vitamin D (500,000 IU) reported in any large randomized controlled trial,” it is possible that these adverse outcomes are related to the dosage, or perhaps to the once-a-year regimen. But the levels of 25-hydroxycholecalciferol achieved in these subjects can also occur with other dosing regimens, so it appears that the safety of all high-dose vitamin D supplementation warrants further examination, said Kerrie M. Sanders, Ph.D., of the University of Melbourne and her associates.

Dr. Sanders and her colleagues performed their single-center study in 2,256 white women aged 70 and older who resided in southern Victoria. They were considered at risk for hip fracture because of their family or personal histories or because they reported recent falls.

The subjects were randomly assigned to receive a single oral dose of vitamin D (cholecalciferol) or a matching placebo at the same time every year for 3–5 years. Lab studies in a subgroup of the subjects showed that the active treatment raised levels of 25-hydroxycholecalciferol an average of 41%, as expected.

There were 5,404 falls during follow-up, involving 74% of the women taking vitamin D and 68% of those taking placebo. The rate of falls was 83 per 100 person-years with vitamin D, compared with 73 per 100 person-years with placebo, a statistically significant difference.

The increase in falls with active treatment was noted in falls that produced fractures, falls that did not produce fractures, and falls that produced soft-tissue injury. The percentage of falls requiring a physician's visit was similar between the two groups of subjects, at approximately 27% in both.

A total of 155 women taking vitamin D sustained 171 fractures during follow-up, compared with 125 women taking placebo who sustained 135 fractures. This translates to a rate of 4.9 fractures per 100 person-years with active treatment and 3.9 fractures per 100 person-years with placebo. These risks did not change after the data were adjusted to account for subjects' calcium intake.

“Contrary to our hypothesis, participants receiving annual high-dose oral cholecalciferol experienced 15% more falls and 26% more fractures than [did] the placebo group. Women not only experienced excess fractures after more frequent falls but also experienced more fractures that were not associated with a fall,” the investigators noted (JAMA 2010;303:1815-22).

“A post hoc analysis found that the increased likelihood of falls in the vitamin D group was exacerbated in the 3-month period immediately following the annual dose, and a similar temporal trend was observed for fractures,” they added.

In an accompanying editorial, Dr. Bess Dawson-Hughes and Susan S. Harris, D.Sc., of the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, said that these study findings should not detract from the importance of “correcting widespread vitamin D deficiency and insufficiency. “There is no evidence for adverse effects of more frequent, lower-dose regimens, so daily, weekly, or monthly dosing with vitamin D3 appears to be the best option for clinicians at this time,” hey noted (JAMA 2010;303:1861-2).

Dr. Dawson-Hughes and Dr. Harris also explored possible explanations for the study's surprising results. It may be that the single large dose of vitamin D triggered a short-term “protective” reaction in which the enzyme that catabolizes it was upregulated, “resulting in decreased blood and tissue levels of 1,25-dihydroxyvitamin D.” This dropoff may have, in turn, raised the risk of falls and fractures. Alternatively, some as-yet unknown benefit of vitamin D therapy may have had the unintended effect of raising fall and fracture risks. For example, the treatment may have improved physical performance, reduced chronic pain, or improved mood, any of which could lead to increased activity and thereby increased chances for falling.

Disclosures: This study was supported by the National Health and Medical Research Council and the Australian Government Department of Health and Ageing. No conflicts of interest were reported by Dr. Sanders and her associates, Dr. Dawson-Hughes, or Dr. Harris.

Recommended Reading

Diabetes 'Zindex' Composite Favors Liraglutide
MDedge Family Medicine
Fenofibrate Adds No Benefit to Diabetes Patients on a Statin
MDedge Family Medicine
Bisphosphonates May Not Raise Fracture Risk
MDedge Family Medicine
'Metabolically Healthy' Obesity Not So Healthy
MDedge Family Medicine
Intensive Glucose Control May Benefit Subgroups
MDedge Family Medicine
Thiazolidinediones Appear Safe for Diabetic Eyes
MDedge Family Medicine
Treatment of Sleep Apnea May Improve Glucose Control
MDedge Family Medicine
Some PCOS Treatments Can Reduce Cardiovascular Risk
MDedge Family Medicine
Bone Loss in Teens on DMPA Tied to Vitamin D
MDedge Family Medicine
Vitamin B Therapy Worsens Renal Function, Vascular Events
MDedge Family Medicine